Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

611
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
611
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

815
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
815
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

653
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
653
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

872
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
872
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

688
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Research progress on acupuncture regulation of pro-inflammatory signaling pathways in the treatment of acute lung injury].

Zhen ci yan jiu = Acupuncture research·2025
Same author

SIRT3 Activation by SGLT2 Inhibitor Mitigates Endothelial-To-Mesenchymal Transition in Dahl Salt-Sensitive Rats Induced by High-Salt Diet.

American journal of hypertension·2025
Same author

Intermedin<sub>1</sub><sub>-</sub><sub>53</sub> improves aging-associated cardiac remodeling and dysfunction via mitochondrial SIRT3-mediated SOD2 deacetylation.

Journal of molecular and cellular cardiology·2025
Same author

SIRT3 sulfhydrylation by hydrogen sulphide: A novel approach to prevent ferroptosis and atrial fibrosis.

Nitric oxide : biology and chemistry·2025
Same author

Ferroptosis in organ fibrosis: Mechanisms and therapeutic approaches.

International immunopharmacology·2025
Same author

The role of SGLT1 in atrial fibrillation and its relationship with endothelial-mesenchymal transition.

Biochemical and biophysical research communications·2025

Related Experiment Video

Updated: Apr 27, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.3K

[Progress in PDE4 targeted therapy for inflammatory diseases].

Shun-de Song1, Hui-fang Tang1

  • 1Zhejiang Respiratory Drugs Research Laboratory， Zhejiang University School of Medicine， Hangzhou 310058， China.

Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences
|July 8, 2014
PubMed
Summary

Phosphodiesterase type 4 (PDE4) inhibitors show promise for treating inflammatory conditions by boosting cAMP levels. Several PDE4 inhibitors are in clinical trials for diseases like asthma and arthritis.

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.2K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.0K

Related Experiment Videos

Last Updated: Apr 27, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

9.3K
Development of Recombinant Proteins to Treat Chronic Pain
10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.2K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Context:

  • Inflammatory diseases pose a significant global health burden.
  • Current treatments for inflammatory conditions have limitations.
  • Targeting specific molecular pathways offers a novel therapeutic approach.

Purpose:

  • To review recent advancements in phosphodiesterase type 4 (PDE4) targeted therapies.
  • To highlight the mechanism of action of PDE4 inhibitors in modulating inflammation.
  • To summarize the clinical progress of various PDE4 inhibitors for inflammatory diseases.

Summary:

  • Phosphodiesterase type 4 (PDE4) is a key enzyme regulating cyclic adenosine monophosphate (cAMP) levels in inflammatory cells.
  • Inhibiting PDE4 increases intracellular cAMP, thereby suppressing inflammatory responses.
  • Several PDE4 inhibitors, including GSK256066, roflumilast, tetomilast, and apremilast, are under clinical investigation for conditions such as asthma, COPD, inflammatory bowel disease, dermatitis, and arthritis.

Impact:

  • PDE4 inhibitors represent a promising class of drugs for managing inflammatory diseases.
  • Successful development of PDE4 inhibitors could offer new treatment options with improved efficacy and safety profiles.
  • This review provides a comprehensive overview of the current landscape and future directions in PDE4-targeted therapy.